For Cynthia Calvillo, when it rains, it pours.
The UFC has released a statement in regards to Calvillo failing an in-competition drug test following her fight against Carla Esparza at UFC 219.
The UFC organization was notified today that the U.S. Anti-Doping Agency (USADA) informed Cynthia Calvillo of a potential Anti-Doping Policy violation involving Carboxy-Tetrahydrocannabinol (“Carboxy-THC”) which is a metabolite of marijuana and/or hashish, above the decision limit of 180 ng/mL, stemming from an in-competition sample collected in conjunction with her recent bout in Las Vegas, Nevada on December 30, 2017, UFC 219: Cyborg vs. Holm.
USADA, the independent administrator of the UFC Anti-Doping Policy, will handle the results management and appropriate adjudication of this case involving Calvillo, as it relates to the UFC Anti-Doping Policy and future UFC participation. Because the Nevada Athletic Commission was the regulatory body overseeing the fight in Las Vegas and has licensing jurisdiction over Calvillo, USADA will work to ensure that the Nevada Athletic Commission has the necessary information to determine its proper judgment of Calvillo’s potential anti-doping violation. Additional information will be provided at the appropriate time as the process moves forward.